| Added by | celine.gongora |
|---|---|
| Group name | EquipeCG |
| Item Type | Journal Article |
| Title | BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients |
| Creator | Laroche-Clary et al. |
| Author | A. Laroche-Clary |
| Author | V. Chaire |
| Author | V. Le Morvan |
| Author | A. Neuville |
| Author | F. Bertucci |
| Author | S. Salas |
| Author | R. Sanfilippo |
| Author | P. Pourquier |
| Author | A. Italiano |
| Abstract | BACKGROUND: This study aimed to determine whether the BRCA1 haplotype was associated with trabectedin efficacy in soft-tissue sarcoma (STS) patients. METHODS: We analysed BRCA1 single-nucleotide polymorphisms (SNPs) in tumour specimens from 135 advanced STS patients enrolled in published phase 2 trials or in a compassionate-use programme of trabectedin. Forty-four advanced STS patients treated with doxorubicin and 85 patients with localised STS served as controls. The 6-month nonprogression rate and overall survival (OS) were analysed according to BRCA1 haplotype using log-rank tests. RESULTS: A favourable BRCA1 haplotype (presence of at least one AAAG allele) was significantly associated with an improved 6-month nonprogression rate. It was the only variable significantly associated with OS. No correlations were found between outcomes for patients with localised or advanced STS treated with doxorubicin. CONCLUSIONS: The BRCA1 haplotype represents a potential DNA repair biomarker that can be used for the prediction of response to trabectedin in STS patients. |
| Publication | British Journal of Cancer |
| Volume | 112 |
| Issue | 4 |
| Pages | 688-692 |
| Date | Feb 17, 2015 |
| Journal Abbr | Br. J. Cancer |
| Language | eng |
| DOI | 10.1038/bjc.2014.624 |
| ISSN | 1532-1827 |
| Library Catalog | PubMed |
| Extra | PMID: 25602962 PMCID: PMC4333490 |
| Tags | Adolescent, Adult, Aged, Antineoplastic Agents, Alkylating, BRCA1 Protein, clinic, Clinical Trials, Phase II as Topic, Compassionate Use Trials, Dioxoles, Drug Resistance, Neoplasm, Female, Haplotypes, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Sarcoma, Soft Tissue Neoplasms, Tetrahydroisoquinolines, Trabectedin, Treatment Outcome, Young Adult |
| Date Added | 2019/05/14 - 12:24:32 |
| Date Modified | 2019/10/24 - 16:36:36 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
